{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:09:19Z","timestamp":1793250559412,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematopoietic stem cell transplantation (HSCT) from haploidentical donors is a viable option for patients lacking HLA-matched donors. Here we report the results of a prospective multicenter phase I\/II trial of transplantation of TCR\u03b1\u03b2 and CD19-depleted peripheral blood stem cells from haploidentical family donors after a reduced-intensity conditioning with fludarabine, thiotepa, and melphalan. Thirty pediatric and 30 adult patients with acute leukemia (<jats:italic>n<\/jats:italic>\u2009=\u200943), myelodysplastic or myeloproliferative syndrome (<jats:italic>n<\/jats:italic>\u2009=\u20096), multiple myeloma (<jats:italic>n<\/jats:italic>\u2009=\u20091), solid tumors (<jats:italic>n<\/jats:italic>\u2009=\u20096), and non-malignant disorders (<jats:italic>n<\/jats:italic>\u2009=\u20094) were enrolled. TCR \u03b1\u03b2\/CD19-depleted grafts prepared decentrally at six manufacturing sites contained a median of 12.1\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> CD34<jats:sup>+<\/jats:sup> cells\/kg and 14.2\u2009\u00d7\u200910<jats:sup>3<\/jats:sup> TCR\u03b1\u03b2<jats:sup>+<\/jats:sup> T-cells\/kg. None of the patients developed grade lll\/IV acute graft-versus-host disease (GVHD) and only six patients (10%) had grade II acute GVHD. With a median follow-up of 733 days 36\/60 patients are alive. The cumulative incidence of non-relapse mortality at day 100, 1 and 2 years after HSCT was 5%, 15%, and 17% for all patients, respectively. Estimated probabilities of overall and disease-free survival at 2 years were 63% and 50%, respectively. Based on these promising results in a high-risk patient cohort, haploidentical HSCT using TCR\u03b1\u03b2\/CD19-depleted grafts represents a viable treatment option.<\/jats:p>","DOI":"10.1038\/s41409-021-01551-z","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T05:04:09Z","timestamp":1640322249000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Results of a multicenter phase I\/II trial of TCR\u03b1\u03b2 and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang A.","family":"Bethge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8099-5903","authenticated-orcid":false,"given":"Matthias","family":"Eyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-9215","authenticated-orcid":false,"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-0628","authenticated-orcid":false,"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-1103","authenticated-orcid":false,"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-7996","authenticated-orcid":false,"given":"Ansgar","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Brecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-7806","authenticated-orcid":false,"given":"Jurgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wiesneth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Westinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Karitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Malchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Siewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-2142","authenticated-orcid":false,"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"1551_CR1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/bmt.2017.34","volume":"52","author":"JR Passweg","year":"2017","unstructured":"Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C. et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2017;52:811\u20137. https:\/\/doi.org\/10.1038\/bmt.2017.34.","journal-title":"Bone Marrow Transpl"},{"key":"1551_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/bjh.13868","volume":"172","author":"N Or-Geva","year":"2016","unstructured":"Or-Geva N, Reisner Y. The evolution of T-cell depletion in haploidentical stem-cell transplantation. Br J Haematol. 2016;172:667\u201384. https:\/\/doi.org\/10.1111\/bjh.13868.","journal-title":"Br J Haematol"},{"key":"1551_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/blood.V61.2.341.341","volume":"61","author":"Y Reisner","year":"1983","unstructured":"Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61:341\u20138.","journal-title":"Blood"},{"key":"1551_CR4","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood.V84.11.3948.bloodjournal84113948","volume":"84","author":"F Aversa","year":"1994","unstructured":"Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, et al. Successful engraftment of T-cell-depleted haploidentical \u201cthree-loci\u201d incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948\u201355.","journal-title":"Blood"},{"key":"1551_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen Z, Prinz I, D\u00e9chanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat Rev Drug Disco. 2020;19:169\u201384. https:\/\/doi.org\/10.1038\/s41573-019-0038-z.","journal-title":"Nat Rev Drug Disco"},{"key":"1551_CR6","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1182\/bloodadvances.2019032409","volume":"3","author":"GJJ Kierkels","year":"2019","unstructured":"Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, et al. Identification of a tumor-specific allo-HLA-restricted \u03b3\u03b4TCR. Blood Adv. 2019;3:2870\u201382. https:\/\/doi.org\/10.1182\/bloodadvances.2019032409.","journal-title":"Blood Adv"},{"key":"1551_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","volume":"39","author":"KT Godder","year":"2007","unstructured":"Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transpl. 2007;39:751\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1705650.","journal-title":"Bone Marrow Transpl"},{"key":"1551_CR8","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.bbmt.2016.08.006","volume":"22","author":"G Li Pira","year":"2016","unstructured":"Li Pira G, Malaspina D, Girolami E, Biagini S, Cicchetti E, Conflitti G, et al. Selective depletion of alphabeta T cells and B cells for human leukocyte antigen-haploidentical hematopoietic stem cell transplantation. A three-year follow-up of procedure efficiency. Biol Blood Marrow Transpl. 2016;22:2056\u201364. https:\/\/doi.org\/10.1016\/j.bbmt.2016.08.006.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1551_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","volume":"15","author":"M Schumm","year":"2013","unstructured":"Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, et al. Depletion of T-cell receptor alpha\/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013;15:1253\u20138. https:\/\/doi.org\/10.1016\/j.jcyt.2013.05.014.","journal-title":"Cytotherapy"},{"key":"1551_CR10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","volume":"124","author":"A Bertaina","year":"2014","unstructured":"Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood. 2014;124:822\u20136. https:\/\/doi.org\/10.1182\/blood-2014-03-563817.","journal-title":"Blood"},{"key":"1551_CR11","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","volume":"132","author":"A Bertaina","year":"2018","unstructured":"Bertaina A, Zecca M, Buldini B, Sacchi N, Algeri M, Saglio F, et al. Unrelated donor vs HLA-haploidentical alpha\/beta T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood. 2018;132:2594\u2013607. https:\/\/doi.org\/10.1182\/blood-2018-07-861575.","journal-title":"Blood"},{"key":"1551_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.clim.2014.03.006","volume":"152","author":"S Ghosh","year":"2014","unstructured":"Ghosh S, Schuster FR, Adams O, Babor F, Borkhardt A, Comoli P, et al. Haploidentical stem cell transplantation in DOCK8 deficiency\u2014successful control of pre-existing severe viremia with a TCRass\/CD19-depleted graft and antiviral treatment. Clin Immunol. 2014;152:111\u20134. https:\/\/doi.org\/10.1016\/j.clim.2014.03.006.","journal-title":"Clin Immunol"},{"key":"1551_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/10245332.2016.1238182","volume":"22","author":"L Kaynar","year":"2017","unstructured":"Kaynar L, Demir K, Turak EE, Ozturk CP, Zararsiz G, Gonen ZB, et al. TcRalphabeta-depleted haploidentical transplantation results in adult acute leukemia patients. Hematology. 2017;22:136\u201344. https:\/\/doi.org\/10.1080\/10245332.2016.1238182.","journal-title":"Hematology"},{"key":"1551_CR14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jaci.2014.04.041","volume":"134","author":"G Kharya","year":"2014","unstructured":"Kharya G, Nademi Z, Leahy TR, Dunn J, Barge D, Schulz A, et al. Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2014;134:1199\u2013201. https:\/\/doi.org\/10.1016\/j.jaci.2014.04.041.","journal-title":"J Allergy Clin Immunol"},{"key":"1551_CR15","first-page":"O154","volume":"53","author":"P Lang","year":"2018","unstructured":"Lang P, Schlegel PG, Meisel R, Schulz A, Greil J, Bader P, et al. Safety and efficacy of TCRalpha\/beta and CD19 depleted haploidentical stem cell transplantation following reduced intensity conditioning in children: results of a prospective multicenter phase I\/II clinical trial. Bone Marrow Transpl. 2018;53:O154.","journal-title":"Bone Marrow Transpl"},{"key":"1551_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","volume":"130","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. Blood. 2017;130:677\u201385. https:\/\/doi.org\/10.1182\/blood-2017-04-779769.","journal-title":"Blood"},{"key":"1551_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/bmt.2015.258","volume":"51","author":"C Mainardi","year":"2016","unstructured":"Mainardi C, Tumino M, Gazzola MV, Rampazzo A, Scarpa M, Messina C. TCRalphabeta CD19 depletion in allogeneic haematopoietic stem cell transplantation performed for Hurler syndrome. Bone Marrow Transpl. 2016;51:438\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.258.","journal-title":"Bone Marrow Transpl"},{"key":"1551_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/bmt.2015.343","volume":"51","author":"M Maschan","year":"2016","unstructured":"Maschan M, Shelikhova L, Ilushina M, Kurnikova E, Boyakova E, Balashov D, et al. TCR-alpha\/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transpl. 2016;51:668\u201374. https:\/\/doi.org\/10.1038\/bmt.2015.343.","journal-title":"Bone Marrow Transpl"},{"key":"1551_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/bmt.2014.58","volume":"49","author":"M Tumino","year":"2014","unstructured":"Tumino M, Mainardi C, Pillon M, Calore E, Gazzola MV, Destro R, et al. Haploidentical TCR A\/B and B-cell depleted hematopoietic SCT in pediatric SAA and aspergillosis. Bone Marrow Transpl. 2014;49:847\u20139. https:\/\/doi.org\/10.1038\/bmt.2014.58.","journal-title":"Bone Marrow Transpl"},{"key":"1551_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1551_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1551_CR22","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1551_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333\u20138. https:\/\/doi.org\/10.1182\/blood-2014-10-609032.","journal-title":"Blood"},{"key":"1551_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/MOH.0b013e32835822dc","volume":"19","author":"EJ Fuchs","year":"2012","unstructured":"Fuchs EJ. Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol. 2012;19:440\u20137. https:\/\/doi.org\/10.1097\/MOH.0b013e32835822dc.","journal-title":"Curr Opin Hematol"},{"key":"1551_CR25","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1182\/blood-2011-07-338822","volume":"118","author":"Y Reisner","year":"2011","unstructured":"Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 2011;118:6006\u201317. https:\/\/doi.org\/10.1182\/blood-2011-07-338822.","journal-title":"Blood"},{"key":"1551_CR26","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/s41375-020-0733-0","volume":"34","author":"DC Roy","year":"2020","unstructured":"Roy DC, Walker I, Maertens J, Lewalle P, Olavarria E, Selleslag D, et al. ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. Leukemia. 2020;34:1907\u201323. https:\/\/doi.org\/10.1038\/s41375-020-0733-0.","journal-title":"Leukemia"},{"key":"1551_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/10428194.2018.1485905","volume":"60","author":"K Sahasrabudhe","year":"2019","unstructured":"Sahasrabudhe K, Otto M, Hematti P, Kenkre V. TCR \u03b1\u03b2+\/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data. Leuk Lymphoma. 2019;60:598\u2013609. https:\/\/doi.org\/10.1080\/10428194.2018.1485905.","journal-title":"Leuk Lymphoma"},{"key":"1551_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3324\/haematol.2011.059378","volume":"97","author":"B Federmann","year":"2012","unstructured":"Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3\/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. 2012;97:1523\u201331. https:\/\/doi.org\/10.3324\/haematol.2011.059378.","journal-title":"Haematologica"},{"key":"1551_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/leu.2010.235","volume":"25","author":"B Federmann","year":"2011","unstructured":"Federmann B, H\u00e4gele M, Pfeiffer M, Wirths S, Schumm M, Faul C, et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3\/CD19 depleted grafts. Leukemia. 2011;25:121\u20139. https:\/\/doi.org\/10.1038\/leu.2010.235.","journal-title":"Leukemia"},{"key":"1551_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1046\/j.1365-2141.2001.02934.x","volume":"114","author":"M Eyrich","year":"2001","unstructured":"Eyrich M, Lang P, Lal S, Bader P, Klingebiel T, Handgretinger R, et al. A prospective analysis of the pattern of immune reconstitution following transplantation of HLA-disparate hematopoietic stem cells from parental donors. Br J Haematol. 2001;114:422\u201332.","journal-title":"Br J Haematol"},{"key":"1551_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","volume":"5","author":"B Rambaldi","year":"2021","unstructured":"Rambaldi B, Kim HT, Reynolds C, Chamling Rai S, Arihara Y, Kubo T, et al. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021;5:352\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2020003005.","journal-title":"Blood Adv"},{"key":"1551_CR32","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1002\/cti2.1171","volume":"9","author":"N Stocker","year":"2020","unstructured":"Stocker N, Gaugler B, Labopin M, Farge A, Ye Y, Ricard L, et al. High-dose post-transplant cyclophosphamide impairs \u03b3\u03b4 T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. Clin Transl Immunol. 2020;9:e1171. https:\/\/doi.org\/10.1002\/cti2.1171.","journal-title":"Clin Transl Immunol"},{"key":"1551_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2019.10.014","volume":"26","author":"J Sanz","year":"2020","unstructured":"Sanz J, Montoro J, Solano C, Valc\u00e1rcel D, Sampol A, Ferr\u00e1 C, et al. Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transpl. 2020;26:358\u201366. https:\/\/doi.org\/10.1016\/j.bbmt.2019.10.014.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1551_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s1083-8791(03)00287-8","volume":"9","author":"M Boeckh","year":"2003","unstructured":"Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transpl. 2003;9:543\u201358. https:\/\/doi.org\/10.1016\/s1083-8791(03)00287-8.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1551_CR35","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","volume":"4","author":"HJ Symons","year":"2020","unstructured":"Symons HJ, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4:3913\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2020001648.","journal-title":"Blood Adv"},{"key":"1551_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bbmt.2016.11.008","volume":"23","author":"SA Srour","year":"2017","unstructured":"Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, et al. Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2017;23:318\u201324. https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.008.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1551_CR37","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.bbmt.2016.04.006","volume":"22","author":"M Solh","year":"2016","unstructured":"Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, et al. Factors predicting graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation: multivariable analysis from a single center. Biol Blood Marrow Transpl. 2016;22:1403\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.006.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1551_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1506002.","journal-title":"N Engl J Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01551-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01551-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01551-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T09:10:37Z","timestamp":1646817037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01551-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01551-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WB: Consultancy and Research Funding\u2014Miltenyi Biotec; Advisory Boards\u2014Celgene, Novartis, Janssen, Gilead. ME: Clinical trial support and advisory boards\u2014Bristol-Myers-Squibb. SM: Data safety monitoring board\u2014Miltenyi, Immunicum; expert panel\u2014Gilead\/Kite, Bellicum; speaker\u2019s fee\u2014Novartis, DNA Prime SA, Cellex, Celgene, Kiadis Pharma, Jazz, Miltenyi; travel support\u2014Cellex, Gilead\/Kite, MSD, Celgene, Kiadis Pharma, Miltenyi. RM: Consulting or Advisory Role\u2014Bluebird Bio, Bellicum Pharmaceuticals, Novartis; Travel, Accommodations, Expenses\u2014Jazz Pharmaceuticals. DN: Advisory board\u2014Cellectis; speakers bureau\u2014Novartis, Daiichi; manuscript preparation support\u2014Novartis. PGS: Advisory board\u2014Bluebird Bio, not related to the topic of this publication. JK: Shareholder Gadeta and inventor on multiple patents dealing with gdT cell-related topics as well as CAR T isolation strategies; Research Support\u2014Miltenyi Biotec, Novartis. HB: Research support: Bayer, Chugai, Erydel, Miltenyi, Polyphor, Sandoz-Hexal (a Novartis Company), Stage (a Celgene Company), Terumo BCT, Uniqure; honoraria\/speakers\u2018 fees\u2014Chugai, Fresenius, Genzyme, Kiadis, medac, Miltenyi, Novartis, Sandoz-Hexal, Terumo BCT; consultancy and advisory boards\u2014Boehringer-Ingelheim, Celgene, Genzyme, medac, Novartis, Sandoz-Hexal, Stage, Terumo BCT; royalties\u2014medac; stocks\u2014Healthineers. KW: Advisory board\u2014Novartis AG, not related to the topics of this publication. SB and CS are employees of Miltenyi Biotec. SH, SK, and MM are employees of Miltenyi Biomedicine. RH: Speakers\u2019 honoraria\u2014Miltenyi Biotec; co-patent holder of the TcR alpha-beta depletion. AB, DB, JG, PL, AS, MS, VV, MW: no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}